



1644 REST AVAILABLE COPY

PATENT
3631-0109P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Lucilla Steinaa et al. Conf.: 5928

Appl. No.: 09/806,703 Group: 1644

Filed: April 30, 2001 Examiner: DIBRINO, MARIANNE

For: NOVEL METHODS FOR THERAPEUTIC
VACCINATION

RECEIVED

MAY 05 2003

LARGE ENTITY TRANSMITTAL FORM
TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, DC 20231

April 25, 2003

Sir:

Transmitted herewith is a Response to Restriction Requirement in
the above-identified application.

The enclosed document is being transmitted via the Certificate
of Mailing provisions of 37 C.F.R. § 1.8.

The enclosed document is being transmitted via facsimile.

The fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL	104	-	92	=	12	\$18	\$216.00
INDEPENDENT	4	-	3	=	1	\$84	\$84.00
<input type="checkbox"/> FIRST PRESENTATION OF A MULTIPLE DEPENDENT CLAIM						\$280	\$0.00
						TOTAL	\$300.00

BEST AVAILABLE COPY

Appl. No. 09/806,703


- Petition for () month(s) extension of time pursuant to 37 C.F.R. §§ 1.17 and 1.136(a). \$0.00 for the extension of time.
- No fee is required.
- Check(s) in the amount of \$300.00 is(are) enclosed.
- Please charge Deposit Account No. 02-2448 in the amount of \$0.00. This form is submitted in triplicate.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By


Leonard R. Svensson, #30,330

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachment(s)

(Rev. 10/15/02)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope to: Commissioner of Patents and Trademarks, Washington

D.C. 20231 on: April 25 2003
(Date of deposit)

BIRCH, STEWART, KOLASCH & BIRCH, LLP

John R. Paul
(Signature)

April 25, 2003
(Date of Signature)



BEST AVAILABLE COPY

127
PATENT
3631-0109P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Lucilla STEINAA et al. Conf.: 5928

Appl. No.: 09/806,703 Group: 1644

Filed: April 30, 2001 Examiner: DIPRINO, Marianne

For: NOVEL METHODS FOR THERAPEUTIC
VACCINATION

RECEIVED

MAY 05 2003

Response to Restriction Requirement

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, DC 20231

April 25, 2003

Sir:

In response to the Office Action issued March 25, 2003, the following amendments and remarks are respectfully submitted in connection with the above-identified application.

AMENDMENTS

IN THE CLAIMS:

Please amend the claims as follows:

67. (Twice Amended) An analogue of human Her2 which is immunogenic in humans, said analogue comprising a substantial part of all known and predicted CTL and B-cell epitopes of the extracellular part of Her2 and including at least one immunodominant foreign T_H epitope.

05/01/2003 AOSMANI 00000003 09806703

01 FC:1201
02 FC:1202

84.00 OP
216.00 OP